The allergy treatment landscape is undergoing a fundamental shift. For decades, people with allergies relied on antihistamines, EpiPens, and avoidance strategies to manage their conditions. But a new wave of biotech companies is developing treatments designed to actually modify the disease itself, offering patients the possibility of long-term protection or even desensitization rather than just symptom relief .

Why Are Allergy Treatments Changing Now?

The push for innovation comes at a critical time. Allergic conditions are rising globally, driven by environmental factors, urbanization, and changing lifestyles. Traditional approaches that simply mask symptoms or require patients to avoid allergens are no longer sufficient for many people, especially those with severe food allergies or multiple environmental sensitivities. This growing burden has created an opportunity for companies to develop what researchers call "disease-modifying approaches" that target the root cause of allergies rather than just treating the symptoms .

The shift represents a fundamental change in how the medical community thinks about allergies. Instead of asking "How do we help patients manage their reactions?" companies are now asking "How do we retrain the immune system to stop overreacting in the first place?"

What Types of New Allergy Treatments Are in Development?

Several promising technologies are reshaping the allergy treatment pipeline. These approaches go far beyond the antihistamines and emergency medications that have dominated allergy care for generations. Here's what's emerging:

• Immunotherapy Vaccines: Short-course injection-based treatments designed to reduce allergic responses before symptoms start. One example is Grassmuno, a grass pollen allergen immunotherapy that received marketing authorization in Germany. It works through just six injections given before hay fever season, compared to months-long treatment schedules required by older subcutaneous immunotherapy products .
• Engineered Peptide Therapies: Advanced immunotherapies that use engineered peptides to "retrain" the immune system by precisely targeting T cells and reversing allergic disease. These treatments, like PVX108 for peanut allergy, don't contain actual peanut proteins, which eliminates the risk of serious side effects from the allergen itself .
• Epicutaneous Immunotherapy Patches: Skin-based treatments that aim to re-educate the immune system through the skin rather than through injections. The VIASKIN peanut patch demonstrated that 46.6% of children aged four to seven years met treatment responder criteria after 12 months of use, compared to just 14.8% in the placebo group .
• Monoclonal Antibodies: Engineered human antibodies designed to block and prevent the allergic cascade. These highly targeted treatments isolate rare human B cells that produce specific antibodies, then re-engineer them to neutralize the most clinically important allergens .
• Toll-Like Receptor Agonists: Allergen-agnostic immunotherapies that activate specific immune receptors to modify the allergic response, offering potential treatment across multiple allergy types .

How Close Are These Treatments to Reaching Patients?

Several candidates are in advanced stages of development. The VIASKIN peanut patch, developed by French biotech company DBV Technologies, announced positive phase 3 trial results in December 2025 and is moving forward with a Biologics License Application (BLA) submission in the United States in the first half of 2026. This represents a major milestone toward potential FDA approval .

Aravax's PVX108, an engineered peptide therapy for peanut allergy, completed recruitment in its phase 2 trial with 95 participants across eight trial sites in the United States and six in Australia. The study enrolled children and adolescents aged four to 17 years old. Headline results are expected in the first half of 2026, with the company preparing to advance the treatment into phase 3 trials .

Allergy Therapeutics' VLP Peanut vaccine candidate, administered via subcutaneous injection, met its primary safety endpoint in phase 1/2a trials. Preliminary data from 48 participants demonstrated that a 2,000-fold increase in the dose was safe and well tolerated, with strong immunomodulating responses observed in biomarker data. The company is now preparing for phase 2b trials .

Steps to Understanding Your Allergy Treatment Options

• Consult an Allergist: Before considering any new treatment, work with a board-certified allergist who can evaluate your specific allergy type, severity, and medical history to determine which approaches might be appropriate for you.
• Ask About Clinical Trials: If you have a severe food allergy or environmental allergy that hasn't responded well to traditional treatments, ask your allergist whether you might be eligible for clinical trials testing new immunotherapy approaches in your area.
• Understand Your Current Treatment: Whether you're using antihistamines, nasal corticosteroids, or carrying an epinephrine auto-injector, make sure you understand how your current medications work and what their limitations are, so you can have an informed conversation about newer options.
• Monitor Emerging Approvals: Keep track of regulatory decisions from the FDA and European Medicines Agency regarding new allergy treatments, as approvals could expand your options significantly over the next few years.

What Does This Mean for People With Allergies Today?

For most people with allergies, these developments won't change their immediate treatment options. Antihistamines, nasal corticosteroids, and epinephrine auto-injectors remain the standard of care. However, the pipeline of new treatments offers hope for people with severe allergies that haven't responded well to existing therapies. The shift toward disease-modifying approaches also signals a broader recognition that allergies deserve more sophisticated treatment strategies than symptom management alone .

The timeline for widespread availability varies. Some treatments, like the VIASKIN peanut patch, could reach patients within the next year or two if regulatory approval proceeds as expected. Others are still in earlier trial phases and may take several more years to develop. Regardless of timeline, the diversity of approaches in development suggests that future allergy patients will have significantly more options tailored to their specific conditions.

For now, people with allergies should continue working closely with their healthcare providers to optimize their current treatment plans while staying informed about emerging options that might become available in the coming years.